Publications

Kirman CR, Aylward LL, Suh M, Harris MA, Thompson CM, Haws LC, Proctor DM, Lin SS, et al. 2013. Physiologically based pharmacokinetic model for humans orally exposed to chromium. Chem Biol Interact 204(1):13-27; doi: 10.1016/j.cbi.2013.04.003. PMID: 23603453.

Tvermoes BE, Finley BL, Unice KM, Otani JM, Paustenbach DJ, Galbraith DA. 2013. Cobalt whole blood concentrations in healthy adult male volunteers following two-weeks of ingesting a cobalt supplement. Food Chem Toxicol 53:432–439; doi: 10.1016/j.fct.2012.11.033. PMID: 23207477.

Paustenbach DJ, Tvermoes BE, Unice KM, Finley BL, Kerger BD. 2013. A review of the health hazards posed by cobalt. Crit Rev Toxicol 43(4):316–362; doi:10.3109/10408444.2013.779633. PMID: 23656559.

Kerger BD, Tvermoes BE, Unice KM, Finley BL, Paustenbach DJ, Galbraith DA. 2013. Cobalt speciation assay for human serum, Part II. Method validation in a study of human volunteers ingesting cobalt (II) chloride dietary supplement for 90 days. Toxicol Environ Chem 95(4):709–718; doi: 10.1080/02772248.2013.792559.

Kerger BD, Gerads R, Gurleyuk H, Thuett KA, Finley BL, Paustenbach DJ. 2013. Cobalt speciation assay for human serum, Part I. Method for measuring large and small molecular cobalt and protein-binding capacity using size exclusion chromatography with inductively-coupled plasma-mass spectroscopy detection. Toxicol Environ Chem 95(4):687–708; doi: 10.1080/02772248.2013.793444.

Finley BL, Unice KM, Kerger BD, Otani JM, Paustenbach DJ, Galbraith DA, Tvermoes BE. 2013. 31-day study of cobalt (II) chloride ingestion in humans: Pharmacokinetics and clinical effects. J Toxicol Environ Health A, 76:1210–1224; doi: 10.1080/15287394.2013.848391. PMID: 24283372.

O’Brien T, Ding H, Suh M, Thompson C, Parsons BL, Harris MA,…, Haws LC, Proctor DM. 2013. Assessment of K-Ras mutant frequency and micronucleus incidence in the mouse duodenum following 90-days of exposure to Cr(VI) in drinking water. Mutat Res 754(1-2):15-21. doi: 10.1016/j.mrgentox.2013.03.008. PMID: 23583686.

Sacks NC. 2013. Avoidable costs in U.S. healthcare: The $200 billion opportunity from using medicines more responsibly. IMS Health, June.

Racz L, Baker PA, Duckworth KL, Heline TR, Woodall BD. 2013. Environmental planning while deployed: Mission hindrance or enhancement? Joint Force Quart 70:30–33.

Flory J, Kanel SR, Racz L, Impellitteri CA, Rendahandi GS, Goltz MN. 2013. Influence of pH on the transport of silver nanoparticles in saturated porous media: Laboratory experiments and modeling. J Nanopart Res 15:1484; doi: 10.1007/s11051-013-1484-x.

Chen Q, Jiang X, Hedgeman E, Knutson K, Gillespie B, Hong B, Lepkowski JM, Franzblau A, et al. 2013. Estimation of age-and sex-specific background human serum concentrations of PCDDs, PCDFs, and PCBs in the UMDES and NHANES populations. Chemosphere 91(6):817-23; doi: 10.1016/j.chemosphere.2013.01.078. PMID: 23466097.

MacDonell MM, Haroun LA, Teuschler LK, Rice ER, Hertzberg RC, Butler JP, Chang Y, Clark S, Johns AP, Perry CS, Garcia SS, Jacobi JH, Scofield MA. 2013. Cumulative risk assessment toolbox: Methods and approaches for the practitioner. J Toxicol 2013:310904; doi: 10.1155/2013/310904. PMID: 23762048.

Sterner TR, Ruark CD, Covington TR, Yu KO, Gearhart JM. 2013. A physiologically based pharmacokinetic model for theoxime TMB-4: Simulation of rodent and human data. Arch Toxicol 87(4):661–680; doi: 10.1007/s00204-012-0987-z. PMID: 23314320.

Gross SA, Avens HJ, Banducci AM, Sahmel J, Panko JM, Tvermoes BE. 2013. Analysis of BTEX groundwater concentrations from surface spills associated with hydraulic fracturing operations. J Air Waste Manage Assoc 63(4):424–432; doi: 10.1080/10962247.2012.759166. PMID: 23687727.

Olchanski N, McInnis-Myers M, Halseth M, Cyr PL, Bockstedt L, Goss TF, Howland RH. 2013. The economic burden of treatment-resistant depression. Clin Ther 35(4):512-522; doi: 10.1016/j.clinthera.2012.09.001. PMID: 23490291.

Thompson CM, Proctor DM, Suh M, Haws LC, Kirman CR, Harris MA. 2013. Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans. Crit Rev Toxicol 43(3):244-274; doi: 10.3109/10408444.2013.768596. PMID: 23445218.

Shah F, Greene N. 2013. Analysis of Pfizer compounds in EPA’s ToxCast chemicals-assay space. Chem Res Toxicol 27(1):86-98; doi: 10.1021/tx400343t. PMID: 24328225.

Naven RT, Swiss R, Klug-McLeod J, Will Y, Greene N. 2013. The development of structure-activity relationships for mitochondrial dysfunction: Uncoupling of oxidative phosphorylation. Toxicol Sci 131(1):271-278; doi: 10.1093/toxsci/kfs279. PMID: 22977170.

Urban JD, Carakostas MC, Brusick DJ. 2013. Steviol glycoside safety: Is the genotoxicity database sufficient? Food Chem Toxicol 51(Jan):386-390; doi: 10.1016/j.fct.2012.10.016. PMID: 23103588.

Mitchell M, Lowe K, Fryzek J. 2012. A multisource approach to improving epidemiologic estimates: Application to global B-cell malignancies. ISRN Oncol 2012:129713; 10.5402/2012/129713. PMID: 23346415.